Thu. Oct 29th, 2020


The Real News Network

BeiGene lung cancer treatment meets main goal in late-stage study

1 min read

People enter a building of biotechnology firm BeiGene Ltd at the Suzhou Industrial Park in Suzhou

(Reuters) – BeiGene Ltd said on Tuesday its cancer therapy combination for treating lung cancer in previously untreated patients met the main goal in a late-stage study.

The therapy, tislelizumab, when administered in combination with chemotherapy helped reduce the risk of cancer progression in patients with squamous non-small cell lung cancer.

(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shounak Dasgupta)